Ultra-low droplet volumes for Underground Tank Platform (UST) and verified stability testing heralds a revolution in key markets
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the Company”), a leading developer and seller of pressure-based instruments, consumables and innovative services for worldwide biotechnology, bioprocessors, cosmetics, nutraceuticals, agrochemicals, and food and beverages, announced today That hemp-derived cannabidiol (“CBD”) processed using the patented Ultra Shear Technology™ platform (“UST™”) has produced high-quality water-soluble nano-emulsions of CBD oil in water that have now demonstrated solid optical and analytical stability after 18 years. Months of production and baseline testing.
CBD is a widely popular remedy for relieving anxiety, depression, and post-traumatic stress disorder, as well as chronic Inflammatory pain and neuropathy. It is FDA approved for use in controlling epileptic seizures in Lennox-Gastaut syndrome And Dravet syndrome. Early research suggests that CBD reduces spasticity in multiple sclerosis It may reduce the severity of associated neurological symptoms Alzheimer’s diseaseAnd Parkinson’s disease, And Schizophrenia. CBD is under investigation as an adjuvant palliative treatment in cancer.
However, CBD is insoluble in water and is poorly absorbed by the human body. the World Health Organization The World Health Organization (WHO) estimates that at least 6% of CBD is absorbed via current oral delivery routes. Thus, most of the cannabidiol that is ingested is lost, passing through the body without being absorbed. Thus, there is great interest in really developing Water Soluble CBD To deliver effective dosage, absorption, bioavailability and benefit of CBD products (eg foods, beverages, treatments).
Dr. Alexander V. Lazarev, Chief Science Officer at PBI, explained: “Nanoemulsions, liposomes and solid lipid nanoparticles present many exciting opportunities as drug and nutrient delivery systems. The smaller the size of oil droplets or particles, the better the stability and bioavailability. Once the droplets/particles reach less than 100nm, nanoemulsions appear optically pure and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability and, most importantly, their shelf life.Moreover, these preparations can be filtered – sterile To comply with Food and Drug Administration (FDA) requirements for injectable drugs.Today we are pleased to report that our enabling, affordable, and scalable floor-to-ceiling tank process has been shown to create nano-emulsions that maintain rock-solid stability, excellent water solubility, and room-grade optical clarity. Heat for at least 18 months, these results offer the potential to significantly increase the shelf life and potency of CBD and many other products. Other oil-based gats in use today. “
Mr. Gary B. Smejkal, Senior Investigator at PBI, explained the company’s breakthrough: “Intensive fluid shear in ground tanks progressively reduces the size of the oil droplets with each cycle, making the method highly tunable while enabling the user to identify and reach the target. Reliably droplet size We have shown that our platform consistently produces CBD nanoemulsions with regular droplet sizes of 30-40 nm that are stable at room temperature for at least 18 months.Drop size measurements by dynamic light scattering (DLS) over time in °C Different heat showed that particle size remains unchanged during prolonged storage at room temperature or refrigeration, a key indicator of nanoemulsion stability.The clarity, measured by UV/VIS spectroscopy, also remains unchanged for extended periods of time. This makes the CBD nanoemulsion optically undetectable when infused in bottled water or other beverages.”
To view a short video clip of PBI’s innovative ground-based tank platform for preparing CBD nanoemulsions, click here.
Hollister, Director of Sales and Marketing at PBI, predicted: “CBD oil nano-emulsions created by UST’s patented processing platform offer the potential to revolutionize the fast-growing cannabis market in foods/drinks and treatments. But CBD is only a microcosm. For Revolution, we believe the Floor Cabinets platform promises to offer a wide range of products covering several key markets, including therapeutic drugs, nutrients, agrochemicals, cosmetics, and foods/beverages.- Duration stability (cold or room temperature), To predictable doses with a much faster onset of effect than other oral/topical forms, we believe the benefits, attractiveness, and adoption by consumers will be enormous.This historic milestone of exceeding every 18 months stability goals position PBI for rapid customer adoption of UST nanoemulsion systems Ours is on commercial release planned for the first half of 2022.”
With an expected compound annual growth rate (CAGR) from 21.2% from 2021 to 2028, the global CBD market is expected to grow from US$ 2.8 billion in 2020 to US$ 13 billion in 2028.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leading developer and sale of innovative, scale-able, pressure-based solutions to the worldwide life sciences and other industries. Our products are based on the unique properties of constant (i.e. static) and alternating (i.e. pressure cycling technology or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and extremely high levels to safely and reproducibly control biomolecular interactions (eg, cell lysis, biomolecule extraction). Our primary focus is on PCT-based product development for biomarkers and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics, and anti-bioterrorism applications. In addition, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (i) the use of patented technology that we recently acquired from BaroFold, Inc. (“BaroFold” technology) to allow entry into the biopharmaceutical contract services sector, and (ii) use the recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create nanoemulsions Stable to immiscible liquids (eg, oils and water) and (ii) the preparation of high-quality, homogeneous, extended-release, or stable, low-acid liquid foods at room temperature that cannot be effectively preserved using current non-thermal techniques.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements or our industry to differ materially from any future results or levels of activity, performance or achievements that we expressed, implied, or inferred by these forward-looking statements. In some cases, you may identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “will,” “expect,” “plan,” “intend,” “expect,” “believe.” , “estimates”, “expects”, “projects”, “potential” or “continued” or negative from these and other similar terms. These statements are merely forecasts based on our current expectations and expectations about future events. They should not be unduly based on these statements In evaluating these statements you must specifically consider various factors Actual events or results may differ materially These and other factors could cause our actual results to differ materially from any forward-looking statement These include risks, uncertainties and other factors, Without limitation, the risks and uncertainties discussed under “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2020, and other reports submitted by the Company from time to time with the SEC. Under no obligation to update any of the information in this statement, except as otherwise required by law.
For more information on PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn and Twitter.
Click on Contacts:
Richard T Schumacher, President and CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 703-8557 (T)
Alexander V. Lazarev, Ph.D. Chief Science Officer (508) 230-1828 (T)
source: biopressure company
View the source version on accesswire.com: